Capricor Therapeutics announced the scale-up to expand manufacturing capacity of CAP-1002 to its new state-of-the-art manufacturing facility, intended for commercial use, subject to regulatory approval, located in San Diego. Furthermore, the Company announced that Cohort B of its HOPE-3, Phase 3 clinical study is enrolling rapidly and is expected to complete full enrollment (n=44) in the second quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.41 USD | +5.05% | +7.98% | +10.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.63% | 170M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization